Search results
Results from the WOW.Com Content Network
AstraZeneca’s Farxiga drug, which treats chronic kidney disease, heart failure and Type 2 diabetes, was among the 10 medications selected last year for the initial round of price negotiations ...
Dapagliflozin is used along with diet, exercise, and usually with other glucose-lowering medications, to improve glycaemic control in adults with type 2 diabetes. . Dapagliflozin, in addition to other SGLT2-inhibitors, was shown to reduce the rate of decline in kidney function and kidney failure in non-diabetic and type 2 diabetic adults when added to the existing treatment
A systematic review and network meta-analysis comparing SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors demonstrated that use of SGLT2 inhibitors was associated with a 20% reduction in death compared with placebo or no treatment. [7] Another systematic review discussed the mechanisms by which SGLT-2 inhibitors improve cardio-renal ...
A review that considered berberine’s effects on heart health found some studies supporting this claim, but due to the high risk of bias, the researchers recommended more clinical trials be ...
AstraZeneca plc (NASDAQ: AZN) presented detailed data from the DARE-19 Phase 3 trial at the American College of Cardiology, evaluating Farxiga (dapagliflozin) to treat hospitalized COVID-19 ...
A forced free trial is a direct-marketing technique, usually for goods sold by regular subscription, in which potential buyers are sent a number of free samples of a product, usually periodic publications. Quite often publishers distribute free copies and the reader is not even asked to subscribe.
AstraZeneca's SGLT-2 inhibitor dapaglifozin has had a difficult path to market, but the company finally got the FDA's go-ahead to market the drug on Wednesday. While SGLT-2 inhibitors are a promising
An experimental drug is a medicinal product (a drug or vaccine) that has not yet received approval from governmental regulatory authorities for routine use in human or veterinary medicine. A medicinal product may be approved for use in one disease or condition but still be considered experimental for other diseases or conditions.